Developer docs
API playgroundTry for free, no card

Search company profiles

Halia Therapeutics

Full company profile

uuid0000ay2

Namestring
Halia Therapeutics
Legal namestring
Halia Therapeutics, Inc.
Websiteurl
haliatx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Halia Therapeutics is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Lehi, Utah, that develops small-molecule therapies targeting chronic inflammation across hematologic, neurologic, metabolic, and oncologic diseases. The company's scientific thesis — branded "genetic resilience" — inverts traditional drug discovery by studying individuals who remain healthy despite carrying high-risk genetic variants, using population-scale pedigrees and genomic data (most notably the Utah Population Database) to identify protective mutations such as the RAB10 variant found in APOE4-carrying families that did not develop Alzheimer's disease. This insight underpins the LRRK2 → RAB10 → NEK7 → NLRP3 inflammasome axis that anchors Halia's pipeline.

The pipeline is led by ofirnoflast (HT-6184), a first-in-class oral allosteric NEK7 modulator that prevents NLRP3 inflammasome assembly. Ofirnoflast has demonstrated a 72% hematologic improvement-erythroid (HI-E) response rate and 67% overall hematologic improvement in Phase 2 lower-risk MDS, with FDA Orphan Drug Designation (Oct 2025) and Fast Track designation (Jun 2026); a global Phase 3 is planned for early 2026. Adjacent programs include HT-4253 (LRRK2 inhibitor for Alzheimer's in APOE4 carriers), HT-10068 (neuropenetrant NEK7 inhibitor for neuroinflammation/metabolic disease), and HT-6105 (hsCRP modulator for cardiovascular risk and inflammatory pain), supported by the GENMOR/GENMOR-AI discovery platform that the company claims reduces discovery timelines by ≥50% and time-to-Phase 2B to one-third the industry average.

Halia is pre-revenue. Its business model is to advance candidates through FDA-regulated clinical trials, secure regulatory approval, and commercialize either independently or via partnership/licensing deals. Near-term commercial pathway is centered on ofirnoflast in lower-risk MDS, with expansion optionality into obesity (HT-6184 + GLP-1 combinations) and Alzheimer's. Distribution today is limited to clinical trial sites (US and India), with a strategic international expansion underway through a partnership with the Department of Health – Abu Dhabi leveraging the Emirati Genome and through a Novo Nordisk Golden Ticket – BioLabs European Award for European lab presence.

Short descriptiontext

Halia Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies that target the LRRK2 → RAB10 → NEK7 → NLRP3 inflammasome axis to treat inflammation-driven diseases including lower-risk MDS, Alzheimer's in APOE4 carriers, and obesity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLehi, United States
HQ citystring
Lehi
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inflammasome inhibitor therapeutics, genetic resilience drug discovery, biopharmaceutical clinical development, NLRP3 inflammasome modulation, human genetics drug discovery
Industry2 codes
PRIMARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAE
Predictive Biomarkers for Therapy Selection (response/non-response stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-Stage Biopharmaceuticals (Inflammation / Inflammasome Therapeutics)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Halia Therapeutics does not currently generate revenue. The company's business model is to advance its pipeline through clinical development, secure regulatory approvals (FDA and international equivalents), and commercialize therapeutic products. Revenue will be generated through product sales following regulatory approval. The company is also pursuing partnership and licensing deals as a potential near-term revenue mechanism.

haliatx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1GENMOR Platform
Description

Proprietary AI-powered discovery engine that identifies protective genetic modifiers in individuals who remain healthy despite carrying high-risk genetic variants

haliatx.com
+1 more record
Core offering1 text field

Halia Therapeutics is a clinical-stage biopharmaceutical company developing resilience-based drug candidates that target the genetically validated LRRK2 → RAB10 → NEK7 → NLRP3 inflammasome axis to treat chronic inflammation-driven diseases. Its lead asset, ofirnoflast (HT-6184), is a first-in-class oral allosteric NEK7 modulator in Phase 2/3 development for lower-risk myelodysplastic syndromes, with additional programs in Alzheimer's (HT-4253), obesity, neuroinflammation (HT-10068), and cardiovascular/inflammatory pain (HT-6105). Discovery is powered by the proprietary GENMOR and GENMOR-AI platforms, which identify protective genetic modifiers in resilient individuals using the Utah Population Database.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 72% hematologic improvement-erythroid (HI-E) response rate at Week 16 in lower-risk MDS patients (N=18 evaluable Stage 1 population)
+4 more records
Product overview1 text field

Halia Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of resilience-based therapies targeting inflammation-driven diseases. The company's core offerings include lead drug candidates Ofirnoflast (HT-6184) for myelodysplastic syndromes and HT-4253 for Alzheimer's disease in APOE4 carriers, supported by two AI-powered discovery platforms: the GENMOR Platform for identifying protective genetic modifiers and GENMOR-AI for accelerating target discovery. Additional programs include HT-10068 for neuroinflammatory/metabolic disorders and HT-6105 for cardiovascular risk and inflammatory pain. The company leverages human genetic resilience insights—studying individuals who remain healthy despite high-risk genetic variants—to develop more precise and safer therapeutics.

Product and service4 records
1Ofirnoflast (HT-6184)
CategoryCore product — Inflammasome / NEK7 modulator therapeutic
Description

First-in-class selective oral allosteric NEK7 modulator designed to prevent formation and promote disassembly of the NLRP3 inflammasome complex. Targets underlying inflammatory drivers of hematologic diseases (lower-risk MDS) and is being evaluated in preclinical and clinical studies for obesity in combination with GLP-1 receptor agonists such as semaglutide. Administered orally at 2mg once daily, 5 days on / 2 days off.

2HT-4253
CategoryCore product — LRRK2 inhibitor neuroprotective therapy
Description

LRRK2 inhibitor designed for early intervention in APOE4 carriers — the highest genetic risk population for late-onset Alzheimer's disease. Based on protective RAB10 suppression observed in resilient APOE4+/+ individuals identified through the Utah Population Database; designed to reduce RAB10 phosphorylation (pRAB10) and provide neuroprotection before clinical symptoms manifest.

3HT-10068
CategoryCore product — Neuropenetrant NEK7 inhibitor
Description

Neuropenetrant NEK7 inhibitor targeting inflammation in neuroinflammatory conditions and metabolic disorders including Type 2 diabetes, MASH, and obesity. Phase 1 start targeted for 4Q26.

4HT-6105
CategoryCore product — Cardiovascular / inflammatory pain therapy
Description

Cardiovascular risk reduction and inflammatory pain program that modulates hsCRP (high-sensitivity C-reactive protein) to target cardiovascular inflammatory risk and inflammatory pain pathways. Currently in discovery.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-06
Description

Strategic partnership leveraging the Emirati Genome dataset to discover genetic resilience factors that protect individuals from disease. Paul Jones, newly appointed as Chief Strategy Officer & GM International Markets, is key to advancing this partnership. The collaboration supports Halia's APOE4 Alzheimer's program by studying individuals who carry the highest-risk genetic variant but never develop the condition.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-03-11
Description

Awarded the Novo Nordisk Golden Ticket – BioLabs European Award for companies working on transformational cardiometabolic and obesity therapies. The award provides fully sponsored BioLabs lab space (one bench, one desk, one year membership) at BioLabs Heidelberg or Paris, with priority admission, access to shared research facilities, and engagement with Novo Nordisk's scientific and business executives. Supports Halia's expansion into the European biotech ecosystem.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage neuroscience biotech developing immuno-neurology therapies for neurodegenerative diseases including Alzheimer's. Comparable to Halia's HT-4253 program targeting APOE4 carriers via genetically validated mechanisms.

TypeEmerging player
Description

Biotech developing therapies for neurodegenerative diseases using genetics-driven target selection and engineered biological molecules. Comparable human-genetics-first approach to drug discovery, overlapping with HT-4253 in Alzheimer's.

TypeDirect peer
Description

AI-driven precision medicine company using machine learning to accelerate small-molecule drug discovery. Comparable platform-based business model and inflammation/oncology therapeutic focus areas.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology, machine learning, and genomics. Closely comparable to Halia's GENMOR-AI approach of integrating population-scale data with ML for target identification and prioritization.

TypeDirect peer
Description

UK-based clinical-stage biotech developing small-molecule NLRP3 inflammasome inhibitors for inflammatory and neurodegenerative diseases. Most direct mechanistic competitor to Halia's NEK7/NLRP3 axis, targeting overlapping indications including neurological and metabolic conditions.

6Inflazome (Roche)
TypeDirect peer
Description

Acquired by Roche in 2020, Inflazome developed small-molecule NLRP3 inflammasome inhibitors. Represents a direct mechanistic competitor now backed by Roche's commercial and clinical development capabilities across inflammation-driven indications.

TypeDirect peer
Description

Clinical-stage biotech developing dapansutril and related NLRP3 inflammasome inhibitors for inflammatory diseases. Comparable mechanistic approach and clinical-stage profile to Halia.

TypeDirect peer
Description

AI/ML-driven drug discovery platform integrating human genetics, genomics, and cellular phenotyping to identify therapeutic targets. Highly comparable platform paradigm to Halia's GENMOR-AI genetic resilience approach.

9Bristol Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical company with established MDS franchise (Reblozyl/luspatercept) and NLRP3 inflammasome assets via IFM Tre subsidiary. Represents both a potential commercial competitor in MDS and a likely partnership/licensing counterparty for Halia.

TypeDirect peer
Description

Subsidiary of BMS (formerly IFM Therapeutics), developing NLRP3 and cGAS-STING pathway inhibitors. Direct mechanistic competitor with significantly greater capital and commercial infrastructure backing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Halia Therapeutics

Clinical-Stage Biopharmaceuticals (Inflammation / Inflammasome Therapeutics)haliatx.com

Halia Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies that target the LRRK2 → RAB10 → NEK7 → NLRP3 inflammasome axis to treat inflammation-driven diseases including lower-risk MDS, Alzheimer's in APOE4 carriers, and obesity.

What Halia Therapeutics does

Halia Therapeutics is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Lehi, Utah, that develops small-molecule therapies targeting chronic inflammation across hematologic, neurologic, metabolic, and oncologic diseases. The company's scientific thesis — branded "genetic resilience" — inverts traditional drug discovery by studying individuals who remain healthy despite carrying high-risk genetic variants, using population-scale pedigrees and genomic data (most notably the Utah Population Database) to identify protective mutations such as the RAB10 variant found in APOE4-carrying families that did not develop Alzheimer's disease. This insight underpins the LRRK2 → RAB10 → NEK7 → NLRP3 inflammasome axis that anchors Halia's pipeline.

The pipeline is led by ofirnoflast (HT-6184), a first-in-class oral allosteric NEK7 modulator that prevents NLRP3 inflammasome assembly. Ofirnoflast has demonstrated a 72% hematologic improvement-erythroid (HI-E) response rate and 67% overall hematologic improvement in Phase 2 lower-risk MDS, with FDA Orphan Drug Designation (Oct 2025) and Fast Track designation (Jun 2026); a global Phase 3 is planned for early 2026. Adjacent programs include HT-4253 (LRRK2 inhibitor for Alzheimer's in APOE4 carriers), HT-10068 (neuropenetrant NEK7 inhibitor for neuroinflammation/metabolic disease), and HT-6105 (hsCRP modulator for cardiovascular risk and inflammatory pain), supported by the GENMOR/GENMOR-AI discovery platform that the company claims reduces discovery timelines by ≥50% and time-to-Phase 2B to one-third the industry average.

Halia is pre-revenue. Its business model is to advance candidates through FDA-regulated clinical trials, secure regulatory approval, and commercialize either independently or via partnership/licensing deals. Near-term commercial pathway is centered on ofirnoflast in lower-risk MDS, with expansion optionality into obesity (HT-6184 + GLP-1 combinations) and Alzheimer's. Distribution today is limited to clinical trial sites (US and India), with a strategic international expansion underway through a partnership with the Department of Health – Abu Dhabi leveraging the Emirati Genome and through a Novo Nordisk Golden Ticket – BioLabs European Award for European lab presence.

Halia Therapeutics firmographics

Firmographics
Name
Halia Therapeutics
Legal name
Halia Therapeutics, Inc.
Website
https://haliatx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Halia Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies that target the LRRK2 → RAB10 → NEK7 → NLRP3 inflammasome axis to treat inflammation-driven diseases including lower-risk MDS, Alzheimer's in APOE4 carriers, and obesity.
Ownership category
akta.pro rank

Halia Therapeutics industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals (Inflammation / Inflammasome Therapeutics)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAE
Predictive Biomarkers for Therapy Selection (response/non-response stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Inflammasome inhibitor therapeutics
  • Genetic resilience drug discovery
  • Biopharmaceutical clinical development
  • NLRP3 inflammasome modulation
  • Human genetics drug discovery

Where Halia Therapeutics is headquartered

Location

Headquarters

HQ city
Lehi
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Halia Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Revenue: As a clinical-stage biopharmaceutical company, Halia Therapeutics does not currently generate revenue. The company's business model is to advance its pipeline through clinical development, secure regulatory approvals (FDA and international equivalents), and commercialize therapeutic products. Revenue will be generated through product sales following regulatory approval. The company is also pursuing partnership and licensing deals as a potential near-term revenue mechanism.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Halia Therapeutics product offering

Product offering

Core offering

Halia Therapeutics is a clinical-stage biopharmaceutical company developing resilience-based drug candidates that target the genetically validated LRRK2 → RAB10 → NEK7 → NLRP3 inflammasome axis to treat chronic inflammation-driven diseases. Its lead asset, ofirnoflast (HT-6184), is a first-in-class oral allosteric NEK7 modulator in Phase 2/3 development for lower-risk myelodysplastic syndromes, with additional programs in Alzheimer's (HT-4253), obesity, neuroinflammation (HT-10068), and cardiovascular/inflammatory pain (HT-6105). Discovery is powered by the proprietary GENMOR and GENMOR-AI platforms, which identify protective genetic modifiers in resilient individuals using the Utah Population Database.

Product overview

Halia Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of resilience-based therapies targeting inflammation-driven diseases. The company's core offerings include lead drug candidates Ofirnoflast (HT-6184) for myelodysplastic syndromes and HT-4253 for Alzheimer's disease in APOE4 carriers, supported by two AI-powered discovery platforms: the GENMOR Platform for identifying protective genetic modifiers and GENMOR-AI for accelerating target discovery. Additional programs include HT-10068 for neuroinflammatory/metabolic disorders and HT-6105 for cardiovascular risk and inflammatory pain. The company leverages human genetic resilience insights—studying individuals who remain healthy despite high-risk genetic variants—to develop more precise and safer therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

  • GENMOR Platform: Proprietary AI-powered discovery engine that identifies protective genetic modifiers in individuals who remain healthy despite carrying high-risk genetic variants
  • GENMOR-AI™

Products and services

  • Ofirnoflast (HT-6184) First-in-class selective oral allosteric NEK7 modulator designed to prevent formation and promote disassembly of the NLRP3 inflammasome complex. Targets underlying inflammatory drivers of hematologic diseases (lower-risk MDS) and is being evaluated in preclinical and clinical studies for obesity in combination with GLP-1 receptor agonists such as semaglutide. Administered orally at 2mg once daily, 5 days on / 2 days off.
  • HT-4253 LRRK2 inhibitor designed for early intervention in APOE4 carriers — the highest genetic risk population for late-onset Alzheimer's disease. Based on protective RAB10 suppression observed in resilient APOE4+/+ individuals identified through the Utah Population Database; designed to reduce RAB10 phosphorylation (pRAB10) and provide neuroprotection before clinical symptoms manifest.
  • HT-10068 Neuropenetrant NEK7 inhibitor targeting inflammation in neuroinflammatory conditions and metabolic disorders including Type 2 diabetes, MASH, and obesity. Phase 1 start targeted for 4Q26.
  • HT-6105 Cardiovascular risk reduction and inflammatory pain program that modulates hsCRP (high-sensitivity C-reactive protein) to target cardiovascular inflammatory risk and inflammatory pain pathways. Currently in discovery.

Quantifiable outcome

  • 72% hematologic improvement-erythroid (HI-E) response rate at Week 16 in lower-risk MDS patients (N=18 evaluable Stage 1 population)
  • +4 more outcomes

Companies that use Halia Therapeutics

Customer profile

Segments4 records

Ideal customer profiles4 records

Halia Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Halia Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Department of Health – Abu DhabicoreStrategic or Co-development Partner · 6 October 2025Strategic partnership leveraging the Emirati Genome dataset to discover genetic resilience factors that protect individuals from disease. Paul Jones, newly appointed as Chief Strategy Officer & GM International Markets, is key to advancing this partnership. The collaboration supports Halia's APOE4 Alzheimer's program by studying individuals who carry the highest-risk genetic variant but never develop the condition.
  • Novo Nordisk / BioLabscoreGTM or Marketing Partner · 11 March 2025Awarded the Novo Nordisk Golden Ticket – BioLabs European Award for companies working on transformational cardiometabolic and obesity therapies. The award provides fully sponsored BioLabs lab space (one bench, one desk, one year membership) at BioLabs Heidelberg or Paris, with priority admission, access to shared research facilities, and engagement with Novo Nordisk's scientific and business executives. Supports Halia's expansion into the European biotech ecosystem.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Halia Therapeutics competitors and assessment

Company assessment

Emerging players

  • Alector: Clinical-stage neuroscience biotech developing immuno-neurology therapies for neurodegenerative diseases including Alzheimer's. Comparable to Halia's HT-4253 program targeting APOE4 carriers via genetically validated mechanisms.
  • Denali Therapeutics: Biotech developing therapies for neurodegenerative diseases using genetics-driven target selection and engineered biological molecules. Comparable human-genetics-first approach to drug discovery, overlapping with HT-4253 in Alzheimer's.

Direct peers

  • Exscientia: AI-driven precision medicine company using machine learning to accelerate small-molecule drug discovery. Comparable platform-based business model and inflammation/oncology therapeutic focus areas.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology, machine learning, and genomics. Closely comparable to Halia's GENMOR-AI approach of integrating population-scale data with ML for target identification and prioritization.
  • NodThera: UK-based clinical-stage biotech developing small-molecule NLRP3 inflammasome inhibitors for inflammatory and neurodegenerative diseases. Most direct mechanistic competitor to Halia's NEK7/NLRP3 axis, targeting overlapping indications including neurological and metabolic conditions.
  • Inflazome (Roche): Acquired by Roche in 2020, Inflazome developed small-molecule NLRP3 inflammasome inhibitors. Represents a direct mechanistic competitor now backed by Roche's commercial and clinical development capabilities across inflammation-driven indications.
  • Olatec Therapeutics: Clinical-stage biotech developing dapansutril and related NLRP3 inflammasome inhibitors for inflammatory diseases. Comparable mechanistic approach and clinical-stage profile to Halia.
  • Insitro: AI/ML-driven drug discovery platform integrating human genetics, genomics, and cellular phenotyping to identify therapeutic targets. Highly comparable platform paradigm to Halia's GENMOR-AI genetic resilience approach.
  • IFM Tre (Bristol Myers Squibb): Subsidiary of BMS (formerly IFM Therapeutics), developing NLRP3 and cGAS-STING pathway inhibitors. Direct mechanistic competitor with significantly greater capital and commercial infrastructure backing.

Broad incumbents

  • Bristol Myers Squibb: Large pharmaceutical company with established MDS franchise (Reblozyl/luspatercept) and NLRP3 inflammasome assets via IFM Tre subsidiary. Represents both a potential commercial competitor in MDS and a likely partnership/licensing counterparty for Halia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Halia Therapeutics social profiles

Digital presence

Halia Therapeutics compliance and trust

Trust signal

Compliance2 records

Halia Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Halia Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Halia Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Halia Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Halia Therapeutics

What does Halia Therapeutics do?

Halia Therapeutics is a clinical-stage biopharmaceutical company developing resilience-based drug candidates that target the genetically validated LRRK2 → RAB10 → NEK7 → NLRP3 inflammasome axis to treat chronic inflammation-driven diseases. Its lead asset, ofirnoflast (HT-6184), is a first-in-class oral allosteric NEK7 modulator in Phase 2/3 development for lower-risk myelodysplastic syndromes, with additional programs in Alzheimer's (HT-4253), obesity, neuroinflammation (HT-10068), and cardiovascular/inflammatory pain (HT-6105). Discovery is powered by the proprietary GENMOR and GENMOR-AI platforms, which identify protective genetic modifiers in resilient individuals using the Utah Population Database.

Is Halia Therapeutics a public or private company?

Halia Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Halia Therapeutics founded?

Halia Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Halia Therapeutics based?

Halia Therapeutics is headquartered in Lehi, United States, in the North America region.

How does Halia Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Halia Therapeutics's main competitors?

Emerging players on record are Alector and Denali Therapeutics. Direct peers are Exscientia, Recursion Pharmaceuticals, NodThera, Inflazome (Roche), Olatec Therapeutics, Insitro and IFM Tre (Bristol Myers Squibb). Bristol Myers Squibb is listed as a broad incumbent.

Does Halia Therapeutics have an API?

No public API is recorded for Halia Therapeutics.

What industry is Halia Therapeutics in?

Halia Therapeutics's product category is Clinical-Stage Biopharmaceuticals (Inflammation / Inflammasome Therapeutics). Its primary akta.pro industry code is HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers), with a secondary code of HLAAAMAE, Predictive Biomarkers for Therapy Selection (response/non-response stratification). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireHalia Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare ConferenceHalia Therapeutics will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 14-16, 2026. CEO David Bearss will deliver an overview of the company's strategy, platform, and clinical programs on September 16. The company's lead program, ofirnoflast, targets lower-risk MDS and other hematologic diseases.Targeted OncologyHT-6184 Advances to Second Stage of Phase 2 Trial in LR-MDSHalia Therapeutics is advancing its HT-6184 drug candidate to the second stage of a Phase 2 clinical trial for lower-risk myelodysplastic syndromes (LR-MDS) following positive initial results. The first cohort of 18 patients demonstrated erythroid responses that exceeded preset requirements, validating the study's primary endpoints and triggering an expansion to enroll an additional 8 to 10 patients. The ongoing trial across multiple sites in India aims to evaluate safety and efficacy by the end of Q2 2025 to support potential regulatory submission.Targeted OncologyFDA Grants Fast Track Designation to Ofirnoflast for Lower-Risk MDSThe FDA has granted fast track designation to ofirnoflast (HT-6184) developed by Halia Therapeutics for the treatment of adults with lower-risk myelodysplastic syndromes. This decision follows Phase 2 trial results demonstrating durable transfusion independence and multilineage hematologic improvement in patients who had exhausted standard therapies.Longevity.TechnologyHalia Therapeutics presents promising Alzheimer’s drug data, outlines upcoming clinical trialHalia Therapeutics presented two posters at the Alzheimer's Association International Conference 2026 (July 12–15) on its LRRK2 inhibitor HT-4253, linking preclinical findings to a planned biomarker-driven Phase 2a trial for Alzheimer's prevention in APOE4 carriers. Preclinical studies demonstrated that HT-4253 inhibited LRRK2 autophosphorylation, reduced pro-inflammatory cytokine secretion, decreased tau phosphorylation, and restored phagocytic function, with a favorable safety profile observed in Phase 1. The company has designed a 48-week once-daily Phase 2a study that will identify participants through population-scale genomics in the UAE, screen candidates using C2N Diagnostics' PrecivityAD2 blood test, and track blood-based biomarkers to assess disease-modifying potential.PR NewswireHalia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer's Prevention in APOE4 CarriersHalia Therapeutics presented two posters at the Alzheimer's Association International Conference (AAIC) 2026 showcasing preclinical data and trial design for its LRRK2 inhibitor HT-4253, aimed at preventing or delaying Alzheimer's disease in APOE4 carriers. The preclinical data demonstrated that HT-4253 engaged its target, reduced neuroinflammation and tau pathology, and restored microglial function in cell-based models. A Phase 2a trial is being designed using population-scale genomics in the UAE to identify pre-symptomatic APOE4 carriers for a 48-week study using C2N Diagnostics' PrecivityAD2 blood test for participant screening.BioSpaceHalia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer’s Prevention in APOE4 CarriersHalia Therapeutics presented two AAIC 2026 posters on its LRRK2 inhibitor HT-4253 for Alzheimer's prevention in APOE4 carriers. Preclinical data show reduced neuroinflammation and tau pathology, and a Phase 2a trial is designed using UAE genomics to identify pre-symptomatic carriers. The trial will assess whether the drug alters disease onset and progression.MorningstarHalia Therapeutics Presents Two AAIC 2026 Posters on HT-4253 for Alzheimer's Prevention in APOE4 CarriersHalia Therapeutics presented two AAIC 2026 posters on its LRRK2 inhibitor HT-4253 for Alzheimer's prevention in APOE4 carriers. Preclinical data show reduced neuroinflammation and tau pathology, and a Phase 2a trial is designed using UAE genomics to identify pre-symptomatic carriers. The company aims to assess whether the drug can alter disease onset and progression.The NationalAbu Dhabi to host clinical trial of proactive treatment that aims to prevent Alzheimer's diseaseAbu Dhabi is launching a clinical trial for the experimental drug HT-4253, developed by Halia Therapeutics, to prevent Alzheimer's disease in high-risk individuals identified via the Emirati Genome Programme. The trials are being led by M42’s Insights Research Organisation and Solutions (IROS) division in collaboration with the emirate's Department of Health, utilizing genomic data from nearly one million citizens to target those carrying the APOE4 gene variant.GulfNewsUAE launches first genomics-driven clinical trial to prevent Alzheimer's, powered by Emirati Genome Programme in Abu DhabiM42's Insights Research Organization and Solutions (IROS), in partnership with the Department of Health – Abu Dhabi and US-based Halia Therapeutics, has launched the UAE's first genomics-driven clinical trial to prevent Alzheimer's disease in Abu Dhabi. The trial will use population-scale genomic data from the Emirati Genome Programme—sequencing over 900,000 genomes—to identify asymptomatic individuals carrying the APOE4 gene variant and evaluate Halia Therapeutics' investigational therapy HT-4253. Halia Therapeutics is also establishing a physical office in Abu Dhabi, reinforcing the emirate's emerging position as a global hub for precision medicine and genomically informed clinical research.MuslimnetworkUAE launches first genomics trial to prevent Alzheimer’sThe UAE has launched its first genomics-driven clinical trial to prevent Alzheimer’s disease, led by M42’s Insights Research Organization and Solutions (IROS) in partnership with the Department of Health – Abu Dhabi and biotechnology company Halia Therapeutics. The study will evaluate Halia Therapeutics' investigational therapy HT-4253 in individuals carrying the APOE4 gene variant, utilizing data from the Emirati Genome Programme which has sequenced over 900,000 genomes. This initiative marks a strategic step in translating large-scale genomic research into practical medical applications for precision medicine in the region.